Clinical Laboratory International

The line has been designed to complement the Beckman Coulter catalogue and includes a broad portfolio of specific protein assays for automated nephelometric testing. TRIMERO’s IMMAGE® kits are supplied as complete solutions, including reagent, calibrator and controls. The product line has been developed to support routine implementation on IMMAGE® workstations while maintaining the analytical consistency required for specific protein testing.

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page Google Webfont Settings: Click to enable/disable Google Webfonts. Google Maps Settings: Click to enable/disable Google Maps.

The MultiNA II is Shimadzu’s microchip-based platform for the automated quality control of DNA and RNA – replacing error-prone manual workflows with a standardized digital QC step. By delivering reliable integrity metrics and work-ing with reusable chips, it reduces hands-on time, late QC failures, and running costs. This lets you focus on real science while supporting more sustainable lab operation.

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page Google Webfont Settings: Click to enable/disable Google Webfonts. Google Maps Settings: Click to enable/disable Google Maps.

Antibiotic resistance has crept up on modern medicine, quietly turning once-routine infections into serious threats. Each year, drug-resistant bacteria blunt the effectiveness of frontline treatments, putting surgeries, cancer therapies and everyday infections at greater risk. Rather than chase an entirely new antibiotic, a team from Cold Spring Harbor Laboratory (CSHL) and Scripps Research has taken a different tack: reviving an old one.

Peptide mapping is one of biopharma’s more thankless jobs. Every monoclonal antibody destined for the clinic must be enzymatically chopped into peptides, separated by liquid chromatography (LC), and fed into a mass spectrometer to check for oxidation, deamidation, clipping and other chemical scars that can blunt a drug’s effectiveness. It works, but it is slow, and demand for the test has long outstripped laboratory capacity.

Researchers at the National Institutes of Health (NIH), Stanford University, Boston University, and several collaborating institutions have identified N-desethyl-fluornitrazene (DFNZ), a metabolite of the synthetic benzimidazole opioid fluornitrazene (FNZ), as a µ-opioid receptor (MOR) superagonist with a safety profile that challenges prevailing assumptions in opioid pharmacology. “Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose,” said Nora D.

The tool allows users to generate a lightweight documentation pack covering five modules: a pack cover and revision register, a supplier questionnaire, product and lot intake records, custody transfer records, and discrepancy follow-up records. The supplier questionnaire is built around criteria and observations defined by the user, without automated approval or scoring, whilst custody transfer records are repeatable rows without electronic signatures or legal attestations.

Addressing variability in cold chain management Cold chain management remains one of the more critical steps in bioprocessing, as non-uniform or inefficient freezing can compromise drug substance integrity. RoSS.BLST is built around fully 21 CFR Part 11 compliant, recipe-driven freezing protocols intended to help minimise batch-to-batch variability during freeze-thaw cycles.

Addressing demand for standardised freezing As cell therapies, regenerative medicine and biobanking continue to expand, laboratories face increasing pressure to preserve valuable cell samples with consistent viability and reproducibility. Standardised controlled-rate freezing is regarded as critical to maintaining cell integrity and ensuring reliable downstream research results. “Every sample matters,” said Alexis MacLeod, Global Product Manager – Consumables & Instruments at Azenta Life Sciences.